The Globo H Antibody Drug Conjugate, OBI-999, has been granted by TFDA to proceed to Phase II Human Clinical Study

1.Date of occurrence of the event: October 21, 2021 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause of occurrence: Globo H Antibody Drug Conjugate (ADC), OBI-999, has been granted by TFDA to proceed to Phase II human clinical study. Potential […]